REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The long-term results show a median OS of 64.8 months for the combination arm compared with 33.7 months for chemotherapy alone — a 31-month improvement and a 38% reduction in risk of death (HR 0.62; 95% CI, 0.45–0.85).
Science Significance
This six-year follow-up demonstrates that adding a PD-1 inhibitor to standard chemotherapy yields durable and substantial survival benefit in RM-NPC — a cancer historically associated with poor long-term outcomes. The nearly doubled median OS indicates that immunotherapy–chemotherapy synergy can transform the natural history of nasopharyngeal carcinoma, validating immune checkpoint blockade as a long-term disease-modifying strategy rather than just a temporary response enhancer. These data deepen our scientific understanding of how persistent immune activation combined with cytotoxic therapy can yield durable remission and long-term survival in head and neck cancers.
Regulatory Significance
The long-term OS data from JUPITER-02 reinforce the existing approval of LOQTORZI with gemcitabine-cisplatin in first-line RM-NPC (granted by the U.S. Food and Drug Administration in 2023). Wikipedia+1 With six-year survival matured, this follow-up strengthens regulatory confidence in the regimen’s sustained benefit and safety profile. The robustness of survival benefit documented may support future label expansions, guideline endorsements, and broader adoption across regions — potentially influencing regulatory reviews and reimbursement decisions worldwide.
Business Significance
Advertisement
For Coherus Oncology, these results are a major commercial milestone. Demonstrating a median OS of over five years positions LOQTORZI plus chemotherapy as a premium standard-of-care regimen in NPC — likely to drive uptake, bolster market penetration, and enhance revenue potential. The data are likely to boost investor confidence, improve the drug’s competitive positioning against other immunotherapies, and validate Coherus’s strategic focus on immuno-oncology. Additionally, the long-term benefit may catalyze new clinical trials exploring LOQTORZI in other head-and-neck or related oncology indications, expanding the company’s pipeline and market reach.
Patients’ Significance
For patients with recurrent or metastatic nasopharyngeal carcinoma — many of whom face limited life expectancy with conventional chemotherapy — the LOQTORZI combination offers a real chance at long-term survival and improved quality of life. Extending median survival from under three years (33.7 months) to over five years (64.8 months) can significantly affect life planning, long-term care, and emotional wellbeing. Importantly, the regimen’s sustained benefit and manageable safety profile provide hope to patients who previously had few durable options, potentially changing standard-of-care expectations in this aggressive cancer type.
Policy Significance
The strength of long-term survival data may influence national oncology treatment guidelines, prompting updates to first-line therapy recommendations for RM-NPC. Health-policy makers and payers might re-evaluate coverage policies, making LOQTORZI plus chemotherapy more accessible. Additionally, as long-term immunotherapy data accumulate, regulatory bodies and healthcare systems may prioritize access to immuno-oncology regimens, adjust funding frameworks, and support expanded screening and early detection programs to maximize benefit in eligible populations.
The six-year follow-up from JUPITER-02 marks a landmark achievement in nasopharyngeal carcinoma treatment: LOQTORZI combined with chemotherapy yields prolonged, meaningful survival gains in a cancer historically difficult to treat. With robust survival, tolerable safety, and growing clinical and commercial momentum, LOQTORZI is poised to redefine the standard of care in RM-NPC. As immuno-oncology continues to advance, these data underscore the transformative potential of checkpoint inhibitors — turning previously terminal diagnoses into chronic, manageable conditions and offering patients renewed hope for long-term survival.
Source: Coherus Oncology, Inc. press release
